Radiation of bilateral adrenal metastases is associated with a high risk of primary adrenal insufficiency
Clinical Endocrinology · 2023
DOI: 10.1111/cen.14911 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Endocrinology, 2023. Verfasst von Justine Herndon und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes and Nutrition, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Adrenal Insufficiency, Adrenal Gland Neoplasms, Adrenal Glands. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Background
Adrenal metastasis is the most common adrenal malignancy and can be bilateral in up to 43% of patients. Radiotherapy (RT) is one option available to treat adrenal metastases. The risk of primary adrenal insufficiency (PAI) after adrenal RT is unclear.
Objective
Determine the incidence and the timeline of PAI in patients undergoing adrenal RT. Design, Setting and Participants Single‐centre longitudinal retrospective cohort study of adult patients with adrenal metastases treated with RT between 2010 and 2021.
Results
Of 56 patients with adrenal metastases treated with adrenal RT, eight (14.3%) patients developed PAI at a median of 6.1 months (interquartile range [IQR]: 3.9–13.8) after RT All patients developing PAI had either unilateral RT in the setting of contralateral adrenalectomy or bilateral adrenal RT. Patients who developed PAI received a median RT dose of 50 Gy (IQR: 44–50 Gy), administered in a median of five fractions (IQR: 5–6). Treated metastases decreased in size and/or metabolic activity on positron emission tomography in seven patients (87.5%). Patients were initiated on hydrocortisone (median daily dose of 20 mg, IQR: 18–40) and fludrocortisone (median daily dose of 0.05 mg, IQR: 0.05–0.05 mg). At the end of the study period, five patients died, all due to extra‐adrenal malignancy, at a median time of 19.7 months (IQR: 16–21.1 months) since RT and median time of 7.7 months (IQR: 2.9–12.5 months) since the diagnosis of PAI.
Conclusion
Patients receiving unilateral adrenal RT with two intact adrenal glands have a low risk of PAI. Patients receiving bilateral adrenal RT have a high risk of PAI and require close monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology, Diabetes and Nutrition, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Endocrinology, Duke Health, Durham, North Carolina, USA.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Justine Herndon, Krishan Jethwa, Irina Bancos
Förderung
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Herndon, J., Hallemeier, C., Jethwa, K., Shariff, A., & Bancos, I. (2023). Radiation of bilateral adrenal metastases is associated with a high risk of primary adrenal insufficiency. Clinical Endocrinology. https://doi.org/10.1111/cen.14911
Vancouver
Herndon J, Hallemeier C, Jethwa K, Shariff A, Bancos I. Radiation of bilateral adrenal metastases is associated with a high risk of primary adrenal insufficiency. Clinical Endocrinology. 2023. doi:10.1111/cen.14911
BibTeX
@article{Herndon2023,
author = {Herndon, Justine and Hallemeier, Christopher and Jethwa, Krishan and Shariff, Afreen and Bancos, Irina},
title = {Radiation of bilateral adrenal metastases is associated with a high risk of primary adrenal insufficiency},
journal = {Clinical Endocrinology},
year = {2023},
doi = {10.1111/cen.14911}
}
EUVIMED